MX2016003077A - Prueba diagnostica molecular para cancer esofagico. - Google Patents
Prueba diagnostica molecular para cancer esofagico.Info
- Publication number
- MX2016003077A MX2016003077A MX2016003077A MX2016003077A MX2016003077A MX 2016003077 A MX2016003077 A MX 2016003077A MX 2016003077 A MX2016003077 A MX 2016003077A MX 2016003077 A MX2016003077 A MX 2016003077A MX 2016003077 A MX2016003077 A MX 2016003077A
- Authority
- MX
- Mexico
- Prior art keywords
- test
- diagnostic test
- molecular diagnostic
- oac
- responsiveness
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan los métodos y composiciones para la identificación de una prueba diagnóstica molecular para adenocarcinoma esofágico (OAC). La prueba define un subtipo molecular novedoso deficiente para la reparación del daño del DNA y hace posible la clasificación de un paciente dentro de este subtipo. La presente invención puede utilizarse para determinar si los pacientes con OAC son sensibles o no sensibles desde el punto de vista clínico a un régimen de tratamiento antes de la administración de cualquier quimioterapia. Esta prueba puede utilizarse con diferentes fármacos que afecten directa o indirectamente el daño o la reparación del DNA, como pueden ser los múltiples fármacos quimioterapéuticos, citotóxicos, normales que actualmente se utilizan. En particular, la presente invención se dirige al uso de ciertas combinaciones de marcadores predictivos, en donde la expresión de los marcadores predictivos se correlaciona con la sensibilidad o no sensibilidad a un régimen terapéutico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1316027.0A GB201316027D0 (en) | 2013-09-09 | 2013-09-09 | Molecular diagnostic test for oesophageal cancer |
| PCT/GB2014/052727 WO2015033172A1 (en) | 2013-09-09 | 2014-09-09 | Molecular diagnostic test for oesophageal cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016003077A true MX2016003077A (es) | 2016-07-21 |
Family
ID=49486941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016003077A MX2016003077A (es) | 2013-09-09 | 2014-09-09 | Prueba diagnostica molecular para cancer esofagico. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160222460A1 (es) |
| EP (1) | EP3044327A1 (es) |
| JP (1) | JP2016531579A (es) |
| KR (1) | KR20160057416A (es) |
| CN (1) | CN105874080A (es) |
| AU (1) | AU2014316823A1 (es) |
| CA (1) | CA2923527A1 (es) |
| GB (1) | GB201316027D0 (es) |
| IL (1) | IL244471A0 (es) |
| MX (1) | MX2016003077A (es) |
| SG (1) | SG11201601721UA (es) |
| WO (1) | WO2015033172A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ712314A (en) | 2013-03-15 | 2021-07-30 | Genentech Inc | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
| AU2015265870B2 (en) | 2014-05-29 | 2020-07-09 | Ventana Medical Systems, Inc. | PD-L1 antibodies and uses thereof |
| SG11201700207WA (en) | 2014-07-11 | 2017-02-27 | Genentech Inc | Anti-pd-l1 antibodies and diagnostic uses thereof |
| EP3254110B1 (en) | 2015-02-03 | 2020-03-18 | Ventana Medical Systems, Inc. | Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1) |
| CN105861741B (zh) * | 2016-06-24 | 2019-10-01 | 河北医科大学第四医院 | Senp3基因及其表达产物作为食管癌的诊治靶标 |
| CN106520925A (zh) * | 2016-10-14 | 2017-03-22 | 浙江大学 | 一种用于检测食道癌的引物组及检测方法 |
| CN107680018A (zh) * | 2017-09-27 | 2018-02-09 | 杭州铭师堂教育科技发展有限公司 | 一种基于大数据及人工智能的高考志愿填报系统及方法 |
| GB201716712D0 (en) | 2017-10-12 | 2017-11-29 | Inst Of Cancer Research: Royal Cancer Hospital | Prognostic and treatment response predictive method |
| CN109295208A (zh) * | 2018-10-26 | 2019-02-01 | 德阳市人民医院 | Pi15作为骨关节炎标志物的应用 |
| CN110246544B (zh) * | 2019-05-17 | 2021-03-19 | 暨南大学 | 一种基于整合分析的生物标志物选择方法及系统 |
| US20220251657A1 (en) * | 2021-01-29 | 2022-08-11 | Board Of Regents, The University Of Texas System | Genomic diagnostic method and kit to diagnose early esophageal cancer and barretts esophagus |
| WO2024097998A1 (en) * | 2022-11-04 | 2024-05-10 | Foundation Medicine, Inc. | Composite immune biomarkers and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6686155B2 (en) * | 2001-06-14 | 2004-02-03 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression |
| US20030021786A1 (en) * | 2001-07-09 | 2003-01-30 | Gevas Philip C. | Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
| US7892740B2 (en) * | 2006-01-19 | 2011-02-22 | The University Of Chicago | Prognosis and therapy predictive markers and methods of use |
| WO2008089465A2 (en) * | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms as sex-specific predictors in cancer therapy |
| WO2010040083A2 (en) * | 2008-10-03 | 2010-04-08 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Gene expression predictors of chemoresistance |
| WO2010093465A1 (en) * | 2009-02-11 | 2010-08-19 | Caris Mpi, Inc. | Molecular profiling of tumors |
| CA2801588A1 (en) * | 2010-06-04 | 2011-12-08 | Bioarray Therapeutics, Inc. | Gene expression signature as a predictor of chemotherapeutic response in breast cancer |
| EP2975399B1 (en) * | 2010-09-15 | 2022-05-11 | Almac Diagnostic Services Limited | Molecular diagnostic test for cancer |
-
2013
- 2013-09-09 GB GBGB1316027.0A patent/GB201316027D0/en not_active Ceased
-
2014
- 2014-09-09 AU AU2014316823A patent/AU2014316823A1/en not_active Abandoned
- 2014-09-09 SG SG11201601721UA patent/SG11201601721UA/en unknown
- 2014-09-09 WO PCT/GB2014/052727 patent/WO2015033172A1/en active Application Filing
- 2014-09-09 KR KR1020167009346A patent/KR20160057416A/ko not_active Application Discontinuation
- 2014-09-09 CN CN201480059197.4A patent/CN105874080A/zh active Pending
- 2014-09-09 US US14/917,925 patent/US20160222460A1/en not_active Abandoned
- 2014-09-09 JP JP2016539638A patent/JP2016531579A/ja active Pending
- 2014-09-09 MX MX2016003077A patent/MX2016003077A/es unknown
- 2014-09-09 EP EP14766775.2A patent/EP3044327A1/en not_active Withdrawn
- 2014-09-09 CA CA2923527A patent/CA2923527A1/en not_active Abandoned
-
2016
- 2016-03-07 IL IL244471A patent/IL244471A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201601721UA (en) | 2016-04-28 |
| US20160222460A1 (en) | 2016-08-04 |
| AU2014316823A1 (en) | 2016-04-28 |
| JP2016531579A (ja) | 2016-10-13 |
| CA2923527A1 (en) | 2015-03-12 |
| KR20160057416A (ko) | 2016-05-23 |
| WO2015033172A1 (en) | 2015-03-12 |
| CN105874080A (zh) | 2016-08-17 |
| EP3044327A1 (en) | 2016-07-20 |
| IL244471A0 (en) | 2016-04-21 |
| GB201316027D0 (en) | 2013-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016003016A (es) | Pruebas diagnosticas moleculares para cancer pulmonar. | |
| MX2016003077A (es) | Prueba diagnostica molecular para cancer esofagico. | |
| MX2013002879A (es) | Prueba de diagnostico molecular para cancer. | |
| EA201391805A1 (ru) | Молекулярно-диагностический тест на рак | |
| MX356802B (es) | Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf. | |
| CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
| MY188938A (en) | Therapeutic, diagnostic and prognostic methods for cancer of the bladder | |
| AR100353A1 (es) | Droga de direccionamiento a glipicano 3 (gpc3) que se administra a un paciente que responde a la terapia con drogas de direccionamiento a gpc3 | |
| WO2014036387A3 (en) | Methods for diagnosis and treatment of cancer | |
| CU20120042A7 (es) | (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer | |
| MX2016002423A (es) | Composiciones y metodos de diagnostico para el tratamiento de glioblastoma. | |
| MD20160016A2 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| EA201500334A1 (ru) | Fgfr3 гибридный ген и лекарственный препарат, нацеленный на него | |
| MX2016012285A (es) | Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf. | |
| BR112015027607A2 (pt) | usos de um ecd de fgfr1 ou uma molécula de fusão de ecd de fgfr1 | |
| BR112018004207A2 (pt) | biomarcadores e métodos de tratamento de câncer | |
| MX2024003382A (es) | Composiciones y metodos para detectar el adn tumoral circulante. | |
| BR112016016932A2 (pt) | Tratamento de neoplasia | |
| CL2016001965A1 (es) | Composición coadyuvante anticancerígena que contiene rip3 expresión del promotor como ingrediente activo, método para seleccionar composición coadyuvante anticancerígena para mejorar la sensibilidad de droga anticancerigena, promoviendo la expresión rip3, y metodo para seguimiento de sensibilidad; medicamento contra el cáncer | |
| BR112015020054A2 (pt) | Método de detectar resistência aos efeitos terapêuticos de um inibidor de akt em uma célula cancerosa | |
| WO2013130465A3 (en) | Gene expression markers for prediction of efficacy of platinum-based chemotherapy drugs | |
| WO2014190311A3 (en) | Defective mismatch repair and benefit from bevacizumab for colon cancer | |
| PL410822A1 (pl) | Trójskładnikowa kombinacja do zastosowania w leczeniu skojarzonym niedrobnokomórkowego raka płuc | |
| UA74937U (ru) | Способ оценки чувствительности злокачественных опухолей к лечебным факторам | |
| TW201612522A (en) | Methods, devices, and reagents for monitoring paclitaxel concentration in plasma for pharmacokinetic-guided dosing of paclitaxel |